CN114949114B - Agilawood-containing traditional Chinese medicine composition for enhancing immunity as well as preparation method, preparation and application thereof - Google Patents
Agilawood-containing traditional Chinese medicine composition for enhancing immunity as well as preparation method, preparation and application thereof Download PDFInfo
- Publication number
- CN114949114B CN114949114B CN202210723558.7A CN202210723558A CN114949114B CN 114949114 B CN114949114 B CN 114949114B CN 202210723558 A CN202210723558 A CN 202210723558A CN 114949114 B CN114949114 B CN 114949114B
- Authority
- CN
- China
- Prior art keywords
- agilawood
- parts
- drying
- extracting
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 230000036039 immunity Effects 0.000 title claims abstract description 45
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 39
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 37
- 241000096284 Gynochthodes officinalis Species 0.000 claims abstract description 36
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 35
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 34
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 32
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 32
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 32
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 22
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 238000002156 mixing Methods 0.000 claims description 41
- 239000000463 material Substances 0.000 claims description 35
- 238000010992 reflux Methods 0.000 claims description 31
- 244000182216 Mimusops elengi Species 0.000 claims description 30
- 239000008187 granular material Substances 0.000 claims description 29
- 238000001035 drying Methods 0.000 claims description 26
- 238000007873 sieving Methods 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 13
- 238000002791 soaking Methods 0.000 claims description 11
- 238000010298 pulverizing process Methods 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 235000021028 berry Nutrition 0.000 claims description 9
- 239000003651 drinking water Substances 0.000 claims description 9
- 235000020188 drinking water Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 244000241838 Lycium barbarum Species 0.000 claims description 6
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 6
- 235000015468 Lycium chinense Nutrition 0.000 claims description 5
- 239000006286 aqueous extract Substances 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 4
- 241000271309 Aquilaria crassna Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 235000013305 food Nutrition 0.000 abstract description 11
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 240000002624 Mespilus germanica Species 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 25
- 239000000706 filtrate Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 17
- 210000003734 kidney Anatomy 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 8
- 210000000628 antibody-producing cell Anatomy 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010013954 Dysphoria Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000037831 Polygonatum sibiricum Species 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- -1 qi tonifying Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- SQWFNVMZGIOFHT-UHFFFAOYSA-N 2,2-bis(4-methoxyphenyl)-5,6-dimethylbenzo[h]chromene Chemical compound C1=CC(OC)=CC=C1C1(C=2C=CC(OC)=CC=2)C=CC(C(C)=C(C)C=2C3=CC=CC=2)=C3O1 SQWFNVMZGIOFHT-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241001533085 Aquilaria sinensis Species 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241001468611 Polygonatum cyrtonema Species 0.000 description 1
- 241000037826 Polygonatum kingianum Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 102100036235 Synaptonemal complex protein 3 Human genes 0.000 description 1
- 101710143175 Synaptonemal complex protein 3 Proteins 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition containing agilawood, which is beneficial to enhancing immunity, and a preparation method, a preparation and application thereof, wherein the Chinese medicinal composition is prepared from the following Chinese medicinal raw materials in parts by weight: 30-70 parts of rhizoma polygonati, 20-60 parts of medlar, 10-30 parts of morinda officinalis, 10-30 parts of American ginseng, 5-20 parts of schisandra chinensis and 3-15 parts of agilawood. Preparing a mixed water extract from the rhizoma polygonati, the medlar and the morinda officinalis; preparing a mixed ethanol extract from the American ginseng and the schisandra chinensis; preparing the agilawood ethanol extract from the agilawood. The components in the traditional Chinese medicine composition have synergistic effect, have the effect of enhancing immunity, and can be applied to preparing medicines or health-care foods for enhancing human immunity.
Description
Technical Field
The invention relates to the field of health-care foods and traditional Chinese medicine preparations, in particular to a traditional Chinese medicine composition containing agilawood and beneficial to enhancing immunity, and a preparation method, a preparation and application thereof.
Technical Field
The health care industry for enhancing immunity has been developed for many years, the growth speed is greatly improved, the good growth trend is shown, the market scale of health care products for enhancing immunity is continuously increased, and the health care products have huge market potential. At present, the health care product for enhancing immunity mainly uses trace elements, vitamins and the like as nutritional supplements to regulate the immunity of organisms, has obvious effects on hypoimmunity caused by the lack of certain elements or the lack of vitamins, and has narrower curative effect and poor effect.
Disclosure of Invention
The invention aims at: (1) providing a traditional Chinese medicine composition for enhancing immunity; (2) Providing a preparation method of the traditional Chinese medicine composition for enhancing immunity; (3) Providing a preparation of the traditional Chinese medicine composition for enhancing immunity; (4) Provides the application of the traditional Chinese medicine composition for enhancing immunity.
The purpose (1) is realized: the invention relates to a Chinese medicinal composition containing agilawood, which is helpful for enhancing immunity, and comprises the following raw materials in parts by weight: 30-70 parts of rhizoma polygonati, 20-60 parts of medlar, 10-30 parts of morinda officinalis, 10-30 parts of American ginseng, 5-20 parts of schisandra chinensis and 3-15 parts of agilawood. Further, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 50 parts of rhizoma polygonati, 40 parts of medlar, 20 parts of morinda officinalis, 20 parts of American ginseng, 10 parts of shizandra berry and 6 parts of agilawood.
The purpose (2) is realized: the method comprises the steps of pretreatment, extraction and post-treatment, and specifically comprises the following steps:
A. pretreating, namely drying and crushing raw materials of rhizoma polygonati, medlar and morinda officinalis in a formula ratio, sieving with a 40-60-mesh sieve to obtain a material a for standby, drying and crushing raw materials of American ginseng and schisandra chinensis in a formula ratio, sieving with a 40-60-mesh sieve to obtain a material b for standby, and drying and crushing agilawood with ethanol extract content of 10-20% and sieving with a 8-12-mesh sieve to obtain agilawood powder for standby;
B. extracting: (1) Adding drinking water with the volume 6-8 times of the weight of the material a into the material a, reflux-extracting for 1-3 times at 95-100 ℃ for 30-90min each time, mixing the extracting solutions, concentrating, and drying to obtain dry paste a; (2) Adding ethanol solution with volume percentage concentration of 30% -50% and weight of 6-8 times of the material b into the material b, reflux-extracting for 1-3 times at 60-80 ℃ for 60-120min each time, mixing the extracting solutions, concentrating, and drying to obtain dry paste b; (3) Adding lignum Aquilariae Resinatum powder into 80-100% ethanol solution with volume percentage concentration of 15-25 times, soaking for 40-80min, reflux extracting at 60-80deg.C for 2-3 times, each time for 60-80min, mixing extractive solutions, concentrating, and drying to obtain lignum Aquilariae Resinatum ethanol extract;
C. post-treatment: mixing and crushing the dry extract a, the dry extract b and the agilawood ethanol extract to obtain a material c, adding a proper amount of auxiliary materials into the material c, and uniformly mixing to obtain the target Chinese medicinal composition which is beneficial to enhancing immunity.
In the step B, the drying is low-temperature vacuum drying, and the drying temperature is 60-80 ℃;
in the step C, the crushing and sieving are realized by crushing and sieving through a 70-90-mesh sieve.
The purpose (3) is realized: the agilawood-containing traditional Chinese medicine composition for enhancing immunity is added with auxiliary materials acceptable in the processing of medicines or health-care foods to prepare granules, powder, tablets, capsules and pills.
The purpose (4) is achieved: the invention relates to an application of a Chinese medicinal composition containing agilawood in preparing medicaments or health-care foods for assisting in improving human immunity.
The rhizoma polygonati in the formula of the invention is the dried rhizome of Polygonatum kingianum Polygonatum kingianum Coll.et Hemsl. Of Liliaceae, recorded in Chinese pharmacopoeia (2020 edition), polygonatum sibiricum Polygonatum sibiricum Red. Or Polygonatum cyrtonema Polygonatum cytonema Hua. Sweet and flat nature. Enter spleen, lung and kidney meridians. Has the effects of tonifying qi and yin, strengthening spleen, moistening lung and tonifying kidney, is used for qi deficiency of spleen and stomach, tiredness and hypodynamia, stomach yin deficiency, dry mouth and eating less, lung deficiency and dry cough, cough with blood caused by fatigue, essence and blood deficiency, soreness of waist and knees, early white beard and hair and internal heat and diabetes, and is a medicament for taking in from a list of articles which are food and medicine. The Ming Yi Bie Lu (miscellaneous records of famous physicians) is to tonify the middle-jiao and qi, dispel wind-dampness, calm the five viscera, and keep the weight and the life long after long-term administration. Modern researches show that taking rhizoma Polygonati crude polysaccharide 100-400mg/Kg for mice with low immunity can obviously increase spleen quality, promote degradation of IκB-alpha, enhance expression of p38 MAPK, NF- κ B p65, iNOS and COX-2, and have good dose dependency, promote nuclear transfer process of NF- κB, promote phagocytosis of macrophages, increase secretion of NO, TNF-alpha and IL-6, and show better immunity enhancing activity.
The medlar in the formula of the invention is mature and dry fruit of the solanaceae plant Lycium barbarum L. The medicine and food homology history is long, and is listed as the top grade in Shennong Ben Cao Jing as long-term taking without aging and cold-resistant summer heat; has the functions of delaying senility and resisting aging, and is also called as 'but old man'. The wolfberry fruit contains various amino acids and special nutritional ingredients such as betaine, zeaxanthin, acid berry red and the like, so that the wolfberry fruit has good health care effect, is recorded in Chinese pharmacopoeia (2020 edition), has the functions of nourishing liver and kidney, replenishing vital essence and improving eyesight, is used for treating consumptive disease and essence deficiency, soreness and weakness of waist and knees, dizziness and tinnitus, impotence and spermatorrhea, internal heat and diabetes, blood deficiency and sallow complexion, and eye dizziness, and is a category of medicine and food homologous catalogue specified in 2002 of Chinese ministry of health. Modern researches show that the intraperitoneal injection of the polysaccharide of the fruit of Chinese wolfberry into normal mice, which is 40 mg/(kg. days) x 7 days, can enhance the activity of inhibiting the proliferation of tumor target cells by macrophages treated by ConA; LBP 20 mg/(kg. days) is administrated for 7 days by intraperitoneal injection, so that the spleen PFC value of the aged mice can be obviously improved to normal adult level, and the medlar has better immunoregulation capability.
The morinda officinalis in the formula of the invention is the dry root of morinda officinalis Morirtda officinalis How of the madder family. The medicinal herbs have the functions of tonifying kidney yang, strengthening tendons and bones and dispelling wind and dampness, and are used for impotence and spermatorrhea, infertility due to cold womb, irregular menstruation, lower abdomen crymodynia, rheumatalgia and flaccidity of tendons and bones, and can be used for the category of health care food products directory. Modern pharmacological researches show that the morinda officinalis decoction can improve the immune function of erythrocytes, enhance the proliferation capacity and IL-2 activity of spleen lymphocytes of aged mice, and regulate and improve the immune function of organisms; can enhance the phagocytic function of the macrophages in the abdominal cavity of the mice, promote the proliferation of lymphocytes in vitro of the mice, and enhance the immune function of the mice with low immune function induced by cyclophosphamide, and the study proves that the morinda officinalis polysaccharide has stronger immune regulation effect.
The American ginseng in the formula of the invention is dried root of American ginseng Panax quinquefolium L of Araliaceae, and is also called American ginseng, american ginseng. The American ginseng is sweet, slightly bitter and cool in taste, has the effects of tonifying lung yin, clearing deficiency fire, promoting the production of body fluid and quenching thirst as recorded in 'tonifying diagram herbal preparation' and 'Qianlong 30 years' herbal schema for picking up the body fluid ', and the American ginseng functional main indications' tonifying qi and nourishing yin, clearing heat and promoting the production of body fluid 'are recorded in' Chinese pharmacopoeia (2015 edition). Is used for qi deficiency and yin deficiency, dysphoria with dysphoria due to deficiency heat, cough and asthma, phlegm and blood, internal heat and thirst, and dry mouth and throat, and is a category of the directory of articles which can be used as health food. Modern researches show that the ginsenoside content in American ginseng is similar to that of ginseng, has a certain guarantee effect on the hypofunction of viscera, hypoimmunity and poor adaptability to environment of middle-aged and elderly people, and comprehensively reflects the effect of American ginseng on regulating the body immunity.
The schisandra chinensis in the formula of the invention is the dried mature fruit of magnoliaceae plant schisandra chinensis Schisandra chinensis (turcz.) baill. The Chinese magnoliavine fruit vision improving, water heating, wind treating, qi descending, digestion promoting, cholera and tendon rotating, bubing and running dolphin cold air, edema eliminating, regurgitation, heart and abdomen distention, thirst quenching, dysphoria heat relieving, alcoholism relieving, tendons and bones strengthening, and the Chinese magnoliavine fruit function mainly treats astringents, qi tonifying, body fluid production promoting, kidney tonifying and heart calming in Chinese pharmacopoeia (2015 edition) are recorded in Japanese China herbal medicine. Is used for treating deficiency and asthma, nocturnal emission, enuresis, frequent urination, chronic diarrhea, spontaneous perspiration, night sweat, body fluid consumption, thirst, internal heat, diabetes, palpitation and insomnia, and is a kind of "directory for health food articles" specified in 2002 by Chinese Ministry of health. Modern medical research shows that the schisandra polysaccharide extracted by traditional leaching and ultrasonic assistance has different degrees of effects of promoting the proliferation of spleen lymphocytes of mice in vitro, wherein the effect of the traditional leaching SCP-0 is strongest, and the effect of the ultrasonic assistance extraction SCP-3 is secondarily that the schisandra polysaccharide SCP-0 reversible cyclophosphamide has good regulation effect on the immune function of animal models with low immunity on the non-specific and specific immune functions of mice.
The agilawood in the formula of the invention is woods containing resin, namely, aquilaria sinensis Aquilaria sinensis (Lour.) belonging to the daphnaceae family. For kidney-warming and heart-smoothing, it is recorded in Ben Cao Xin Zao (new edition), but it is better to save trouble and use one herb for kidney-smoothing with Huang Lian and Rou Gui. However, it is used for tonifying heart and kidney, and it is not necessary to grind it with water, and it is sliced into powder and then combined with heart and kidney tonic to treat qi-moving and pain-relieving, warming middle energizer and vomiting and relieving asthma, which is recorded in Chinese pharmacopoeia (2015 edition). Can be used for treating chest and abdominal distention, pain, emesis, singultus due to stomach cold, and dyspnea due to deficiency of the kidney and adverse qi. Modern researches show that agilawood chromone HHHX-5 inhibits immune system diseases, inhibits autonomous and innate immunity by inhibiting STAT3 and NFKB channels, inhibits mast cell histamine release, reduces mouse injury behavior, and has a certain cell immunoregulation function.
The invention has the beneficial effects that:
(1) The invention is compatible with the whole prescription, the effects of invigorating qi and nourishing yin, strengthening spleen, moistening lung, tonifying kidney and replenishing essence are provided as monarch, the medlar and American ginseng are used as ministerial drugs for nourishing liver and kidney, replenishing vital essence and improving eyesight, the medlar and American ginseng are used as ministerial drugs for replenishing qi and nourishing yin, and clearing heat and promoting fluid production, the morinda officinalis is matched with the schisandra chinensis for astringing and astringing, tonifying kidney and calming heart as adjuvant, the agilawood is used for warming kidney and activating heart, and the qi are provided for enabling the whole prescription to tonify kidney and receive qi, nourishing liver and kidney, tonifying qi and nourishing yin, and no eighteen-effect and nineteen-effect are provided.
(2) By adopting the preparation method, the mixed water extract prepared from rhizoma polygonati, medlar and morinda officinalis in the prescription improves the dissolution of active substances such as crude polysaccharide, glycoside, aglycone and the like in the rhizoma polygonati, medlar and morinda officinalis; the mixed ethanol extract is prepared from the Chinese medicinal materials of the American ginseng and the schisandra chinensis, so that the dissolution of the medicinal components of the ginsenoside, the schizandrin A and the like is increased; the agilawood amount in the prescription is small, and the agilawood ethanol extract prepared from the agilawood in the prescription is singly extracted, so that the extraction rate of the agilawood active ingredients can be greatly improved; the classified extraction can fully dissolve water-soluble and alcohol-soluble components of various medicines, improves the extraction transfer rate of medicinal effect substances, promotes the medicinal components to fully play a synergistic effect, improves the immunity enhancing effect, and is better applied to preparing medicines or health-care foods for improving human immunity.
(3) By adopting the formula and the preparation method, the components are synergistic, the immunity enhancing effect is obviously improved, and the dosage of the traditional Chinese medicine raw materials can be effectively reduced.
Drawings
FIG. 1 is a schematic diagram of the process flow of the present invention.
Detailed Description
The invention is further described below with reference to examples and figures, but is not limited in any way, and any alterations or substitutions based on the teachings of the invention are within the scope of the invention.
The traditional Chinese medicine composition for enhancing immunity provided by the invention comprises, by weight, 30-70 parts of rhizoma polygonati, 20-60 parts of wolfberry fruit, 10-30 parts of morinda officinalis, 10-30 parts of American ginseng, 5-20 parts of schisandra chinensis and 3-15 parts of agilawood, and is prepared by the steps of pretreatment, extraction and post-treatment, and specifically comprises the following steps:
A. pretreating, namely drying and crushing raw materials of rhizoma polygonati, medlar and morinda officinalis in a formula ratio, sieving with a 50-mesh sieve to obtain a material a for standby use, drying and crushing raw materials of American ginseng and schisandra chinensis in a formula ratio, sieving with a 50-mesh sieve to obtain a material b for standby use, and drying and crushing agilawood with the ethanol extract content of 10% -20% and sieving with a 10-mesh sieve to obtain agilawood powder for standby use;
B. extracting: (1) Adding drinking water with the volume 6-8 times of the weight of the material a into the material a, reflux-extracting for 1-3 times at 95-100 ℃ for 30-90min each time, mixing the extracting solutions, concentrating under 0.060MPa at 60 ℃, and vacuum drying at 60 ℃ to obtain dry paste a; (2) Adding ethanol solution with volume percentage concentration of 30% -50% v/v, which is 6-8 times of the weight of the material b, into the material b, reflux-extracting for 1-3 times at 60-80 ℃ for 60-120min each time, mixing the extracting solutions, and concentrating under 0.060MPa at 60 ℃ to obtain dry paste b; (3) Adding lignum Aquilariae Resinatum powder into 80-100% v/v ethanol solution with 15-25 times of volume percentage concentration, soaking for 40-80min, reflux extracting at 60-80deg.C for 2-3 times each for 60-80min, mixing extractive solutions, and concentrating at 60 deg.C under 0.060MPa to obtain lignum Aquilariae Resinatum ethanol extract;
C. post-treatment: mixing and pulverizing the dry extract a, the dry extract b and the ethanol extract of eaglewood, and sieving with a 80-mesh sieve to obtain a material c, thereby preparing the target traditional Chinese medicine composition.
The preparation of the Chinese medicinal composition for enhancing immunity is prepared by adding acceptable auxiliary materials in food processing into the Chinese medicinal composition for enhancing immunity, and preparing powder, tablets, capsules, granules and pills. Adding proper amount of auxiliary materials into the material c, and uniformly mixing to prepare the target preparation. 20-30g of the traditional Chinese medicine composition is used in each 100g of the preparation.
The application of the agilawood-containing traditional Chinese medicine composition for enhancing immunity is the application of the agilawood-containing traditional Chinese medicine composition for enhancing immunity in preparation of medicines or health-care foods for enhancing human immunity.
The invention is further illustrated by the following examples:
example 1
Weighing 30g of rhizoma polygonati, 20g of medlar, 10g of morinda officinalis, 10g of American ginseng, 5g of shizandra berry and 3g of agilawood, crushing the rhizoma polygonati, the medlar and the morinda officinalis, sieving with a 50-mesh sieve, adding 6 times of drinking water, carrying out reflux extraction for 3 times at 95-100 ℃ for 60min each time, combining the filtrates, and concentrating under the conditions of 0.060MPa and 60 ℃ to obtain dry extract a; reflux extracting radix Panacis Quinquefolii and fructus Schisandrae chinensis with 7 times of 40% v/v ethanol solution at 60-80deg.C for 3 times, 60min each time, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain dry extract b; adding 20 times of 95% v/v ethanol solution, reflux extracting at 60-70deg.C for 2 times, soaking for 40min each time, reflux extracting for 60min, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain ethanol extract of lignum Aquilariae Resinatum; pulverizing and mixing the dry extract a, the dry extract b and the ethanol extract of lignum Aquilariae Resinatum to obtain the target Chinese medicinal composition.
Example 2
Weighing 70g of rhizoma polygonati, 60g of medlar, 30g of morinda officinalis, 30g of American ginseng, 20g of shizandra berry and 15g of agilawood, crushing the rhizoma polygonati, the medlar and the morinda officinalis, sieving with a 50-mesh sieve, adding 8 times of drinking water, carrying out reflux extraction for 3 times at 95-100 ℃ for 70min each time, combining the filtrates, and concentrating under the conditions of 0.060MPa and 60 ℃ to obtain dry extract a; adding radix Panacis Quinquefolii and fructus Schisandrae into 8 times of 50% v/v ethanol solution, reflux extracting at 60-80deg.C for 3 times each for 70min, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain dry extract b; adding 20 times of 95% v/v ethanol solution, reflux extracting at 60-70deg.C for 3 times, soaking for 60min each time, reflux-extracting for 60min, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain ethanol extract of lignum Aquilariae Resinatum; pulverizing and mixing the dry extract a, the dry extract b and the ethanol extract of lignum Aquilariae Resinatum to obtain the target Chinese medicinal composition.
Example 3
Weighing 50g of rhizoma polygonati, 40g of medlar, 20g of morinda officinalis, 20g of American ginseng, 10g of shizandra berry and 6g of agilawood, crushing the rhizoma polygonati, the medlar and the morinda officinalis, sieving with a 50-mesh sieve, adding 5 times of drinking water, carrying out reflux extraction for 2 times at 95-100 ℃ for 30min each time, combining the filtrates, and concentrating at the temperature of 0.060MPa and 60 ℃ to obtain dry extract a; adding radix Panacis Quinquefolii and fructus Schisandrae into 8 times of 60% v/v ethanol solution, reflux extracting at 60-80deg.C for 3 times, 50min each time, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain dry extract b; adding lignum Aquilariae Resinatum powder into 95% v/v ethanol solution of 25 times weight, reflux extracting at 60-70deg.C for 2 times, soaking for 60min each time, reflux extracting for 60min, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain lignum Aquilariae Resinatum ethanol extract; pulverizing and mixing the dry extract a, the dry extract b and the ethanol extract of lignum Aquilariae Resinatum to obtain the target Chinese medicinal composition.
Example 4
Weighing 60g of rhizoma polygonati, 50g of medlar, 20g of morinda officinalis, 20g of American ginseng, 20g of shizandra berry and 15g of agilawood, crushing the rhizoma polygonati, the medlar and the morinda officinalis, sieving with a 50-mesh sieve, adding 8 times of drinking water, carrying out reflux extraction for 3 times at 95-100 ℃ for 90min each time, combining the filtrates, and concentrating under the conditions of 0.060MPa and 60 ℃ to obtain dry extract a; adding radix Panacis Quinquefolii and fructus Schisandrae into 8 times of 50% v/v ethanol solution, reflux extracting at 60-80deg.C for 3 times each for 2 hr, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain dry extract b; adding lignum Aquilariae Resinatum powder into 90% v/v ethanol solution of 25 times weight, reflux extracting at 60-70deg.C for 3 times, soaking for 80min each time, reflux extracting for 80min, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain lignum Aquilariae Resinatum ethanol extract; pulverizing and mixing the dry extract a, the dry extract b and the ethanol extract of lignum Aquilariae Resinatum to obtain the target Chinese medicinal composition.
Example 5
Weighing 40g of rhizoma polygonati, 40g of medlar, 15g of morinda officinalis, 15g of American ginseng, 10g of shizandra berry and 12g of agilawood, crushing the rhizoma polygonati, the medlar and the morinda officinalis, sieving with a 50-mesh sieve, adding 8 times of drinking water, carrying out reflux extraction for 3 times at 95-100 ℃ for 45min each time, combining the filtrates, and concentrating at the temperature of 0.060MPa and 60 ℃ to obtain dry extract a; adding 6 times of 50% v/v ethanol solution into radix Panacis Quinquefolii and fructus Schisandrae, reflux extracting at 60-80deg.C for 2 times, each time for 90min, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain dry extract b; adding 15 times of 85% v/v ethanol solution, reflux extracting at 60-70deg.C for 2 times, soaking for 70min each time, reflux extracting for 40min, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain ethanol extract of lignum Aquilariae Resinatum; pulverizing and mixing the dry extract a, the dry extract b and the ethanol extract of lignum Aquilariae Resinatum to obtain the target Chinese medicinal composition.
Example 6
Weighing 50g of rhizoma polygonati, 40g of medlar, 20g of morinda officinalis, 20g of American ginseng, 10g of shizandra berry and 6g of agilawood, crushing the rhizoma polygonati, the medlar and the morinda officinalis, sieving with a 50-mesh sieve, adding 7 times of drinking water, carrying out reflux extraction for 2 times at 95-100 ℃ for 60min each time, combining the filtrates, and concentrating under the conditions of 0.060MPa and 60 ℃ to obtain dry extract a; reflux extracting radix Panacis Quinquefolii and fructus Schisandrae chinensis with 7 times of 40% v/v ethanol solution at 60-80deg.C for 2 times each for 60min, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain dry extract b; adding 20 times of 90% v/v ethanol solution, reflux extracting at 60-70deg.C for 3 times, soaking for 50min each time, reflux extracting for 60min, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain ethanol extract of lignum Aquilariae Resinatum; pulverizing and mixing the dry extract a, the dry extract b and the ethanol extract of lignum Aquilariae Resinatum to obtain the target Chinese medicinal composition.
As shown in fig. 1, the prepared traditional Chinese medicine composition is added with dextrin and proper amount of 50% v/v ethanol to prepare soft materials, wet granules, drying, granule finishing and split charging in sequence, and the mass ratio of the granule to the traditional Chinese medicine composition is 100:25.
example 7
The following efficacy tests were performed on the traditional Chinese medicine composition prepared in example 6:
experimental animals: SPF-class male Balb/c mice weighing 20+ -2 g, were male and female halves, and were offered by Beijing Fu Biotechnology Co., ltd.
Experimental facilities, reagents: electronic balance, vernier caliper (precision 0.02 mm), sheep Red Blood Cell (SRBC), microinjector (50 μl), etc.
Sample: the granules for enhancing immunity prepared in example 6 are prepared by respectively taking 7.5g, 15g and 22.5g of pure water to 150mL, and fully mixing the granules to obtain low, medium and high dosage gastric juice.
The experimental method comprises the following steps: mice were randomly divided into 2 groups: i.e., low, medium, high, and control groups of 12 samples each. The gastric lavage amount of the sample group is 20 mL/kg.bw, the control group is given with an equal volume of physiological saline once a day, each mouse is intraperitoneally injected with 2% SRBC for 0.2mL for immunization on the 26 th day of continuous gastric lavage, after continuous gastric lavage for 4 days, the thickness of the left rear toe is measured, and the average value is obtained after 3 times of measurement; the measurement sites were then subcutaneously injected with 20% srbc, 20 μl each, and the left hind toe thickness was measured 24 hours after injection, and the average was taken 3 times. The results are shown in Table 1:
TABLE 1 Effect of the immunity-enhancing granule prepared in example 6 on delayed type allergy of mice
| Dosage (g/kg, bw) | Animal number (only) | Toe swelling degree (mm) |
| Control group | 12 | 0.53±0.20 |
| Low dose group | 12 | 0.69±0.20 |
| Medium dose group | 12 | 0.83±0.23** |
| High dose group | 12 | 0.78±0.24* |
Note that: * P <0.01 compared to control group; * Indicating P <0.05 compared to the control group.
The experimental results show that: the toe swelling degree of the medium and high dose sample groups is remarkably different from that of the control group, which shows that the immunity enhancing granule prepared in the example 6 can enhance the immune response of mice and improve the immunity of the mice.
Example 8
The following efficacy tests were performed with the immunity-enhancing traditional Chinese medicine composition prepared in example 6:
experimental animals: SPF-class male Balb/c mice weighing 20+ -2 g, were male and female halves, and were offered by Beijing Fu Biotechnology Co., ltd.
Experimental facilities, reagents: carbon dioxide incubator, thermostatic water bath, centrifuge, surgical instrument, slide frame, 200 mesh screen, SRBC, complement (guinea pig serum), hank's solution, RPMI1640 culture solution, SA buffer solution, agarose.
Sample: the granules for enhancing immunity prepared in example 6 are prepared by respectively taking 7.5g, 15g and 22.5g of pure water to 150mL, and fully mixing the granules to obtain low, medium and high dosage gastric juice.
The experimental method comprises the following steps: mice were randomly divided into 2 groups: i.e., low, medium, high, and control groups of 12 samples each. The method comprises the steps of (1) performing gastric lavage on a sample group with the volume of 20mL/kg & bw, administering an equal volume of physiological saline to a control group once a day, performing intraperitoneal injection of 2% SRBC for 0.2mL of immunity on each mouse on the 30 th day of continuous gastric lavage, performing cervical dislocation for 4 days after continuous gastric lavage, killing, taking out spleen, placing the spleen in a small plate containing Hank's liquid, lightly grinding the spleen to prepare cell suspension, filtering the cell suspension by a 200-mesh screen or grinding the spleen by 4 layers of gauze, centrifuging (1000 r/min) for 10min, washing the cell suspension by Hank's liquid for 2 times, finally suspending the cell suspension in 5mL of RPM 1640 culture liquid, counting the cell, and adjusting the cell concentration to 5x10 6 And each mL. Cells may also be suspended in 8mL hank's solution.
Heating and dissolving surface culture medium (1 g agarose and double distilled water to 100 mL), placing in 45-50 ℃ water bath for heat preservation, mixing with an equal amount of Hank's liquid with pH of 7.2-7.4 and 2 times concentration, subpackaging into small test tubes, adding 50 mu L of 10% SRBC (v/v prepared by SA buffer solution) into each tube, rapidly and uniformly mixing 20 mu L of spleen cell suspension (5X 106/mL) or 25 mu L of spleen cell suspension into the tubes, pouring onto a glass slide with a brushed agarose thin layer, making parallel pieces, after agar is solidified, horizontally buckling the glass slide on a sheet frame, placing into a carbon dioxide incubator for incubation for 1-1.5 h, then adding complement (1:8) diluted by SA buffer solution into a groove of the glass slide frame, continuously incubating for 1-1.5 h, and counting the number of hemolysis plaques. The results are shown in Table 2:
TABLE 2 Effect of the immunity enhancing granules prepared in EXAMPLE 6 on mouse antibody-producing cells
| Dosage (g/kg, bw) | Animal number (only) | Number of antibody-producing cells/10 6 (spleen cells) |
| Control group | 12 | 419.58±76.17 |
| Low dose group | 12 | 473.75±97.24 |
| Medium dose group | 12 | 508.33±87.97* |
| High dose group | 12 | 527.92±89.81* |
Note that: * Indicating P <0.05 compared to the control group.
The experimental results show that: the number of the mouse antibody-producing cells in the medium-high dose sample group is obviously different from that of the mouse antibody-producing cells in the control group, which indicates that the immunity-enhancing granule prepared in the example 6 is beneficial to enhancing the immunity of mice and improving the number of the mouse antibody-producing cells.
Example 9 comparative test study
(1) Preparation of Chinese medicine extract
Respectively pulverizing rhizoma Polygonati, fructus Lycii and radix Morindae officinalis, sieving with 50 mesh sieve, adding 5 times of purified water, reflux-extracting at 95-100deg.C for 2 times for 30min each time, mixing filtrates, concentrating at 60 deg.C under 0.060MPa, and respectively preparing rhizoma Polygonati water extract, fructus Lycii water extract and radix Morindae officinalis water extract;
respectively taking radix Panacis Quinquefolii and fructus Schisandrae, respectively adding 8 times of 60% v/v ethanol solution, reflux extracting at 60-80deg.C for 3 times, 50min each time, mixing filtrates, concentrating at 60 deg.C under 0.060MPa to obtain dry extract, and respectively preparing radix Panacis Quinquefolii ethanol extract and fructus Schisandrae ethanol extract;
adding lignum Aquilariae Resinatum powder into 95% v/v ethanol solution of 25 times weight, reflux extracting at 60-70deg.C for 2 times, soaking for 60min each time, reflux extracting for 60min, mixing filtrates, and concentrating at 60 deg.C under 0.060MPa to obtain lignum Aquilariae Resinatum ethanol extract.
(2) Preparation: referring to the preparation method of the granule of the embodiment 6, the rhizoma polygonati aqueous extract, the medlar aqueous extract, the morinda officinalis aqueous extract, the American ginseng ethanol extract, the schisandra chinensis ethanol extract and the agilawood ethanol extract are respectively prepared into granules to obtain rhizoma polygonati granules, medlar granules, morinda officinalis granules, american ginseng granules, schisandra chinensis granules and agilawood granules.
(3) Drug efficacy test study: the pharmacodynamic test study was conducted with reference to example 8, and the drug efficacy test study was conducted with the Polygonatum sibiricum granule, lycium barbarum granule, morinda officinalis granule, american ginseng granule, schisandra chinensis granule, and eaglewood granule, which were test groups 1-6 in sequence, 22.5g (high dose) of the corresponding granule was added with pure water to 150mL, and the mixture was thoroughly mixed, and test samples 1-6 were obtained in sequence. The experimental results show that: there was a significant difference in the number of mouse antibody-producing cells in test groups 1 to 6 compared with the high-dose group of the Chinese medicinal composition of example 6, and the number of mouse antibody-producing cells in test groups 1 to 6 was lower than that in the low-dose group (7.5 g) of the Chinese medicinal composition of example 6.
In conclusion, the components in the formula of the invention are synergistic, the immunity enhancing effect is obviously improved, and the dosage of the medicament is effectively reduced.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, alternatives, and improvements that fall within the spirit and scope of the invention.
Claims (9)
1. The traditional Chinese medicine composition for enhancing immunity is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight: 30-70 parts of rhizoma polygonati, 20-60 parts of medlar, 10-30 parts of morinda officinalis, 10-30 parts of American ginseng, 5-20 parts of schisandra chinensis and 3-15 parts of agilawood.
2. The traditional Chinese medicine composition for enhancing immunity according to claim 1, which is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight: 50 parts of rhizoma polygonati, 40 parts of medlar, 20 parts of morinda officinalis, 20 parts of American ginseng, 10 parts of shizandra berry and 6 parts of agilawood.
3. The method of claim 1, wherein the step of preparing a mixed aqueous extract from the sealwort, wolfberry and morinda officinalis; preparing a mixed ethanol extract from the American ginseng and the schisandra chinensis; preparing the agilawood ethanol extract from the agilawood.
4. The Chinese medicinal composition for enhancing immunity as claimed in claim 3, wherein,
the volume percentage concentration of the ethanol solution used by the mixed ethanol extract is 30-50%;
the volume percentage concentration of the ethanol solution used by the agilawood ethanol extract is 80% -100%.
5. The method for preparing the traditional Chinese medicine composition for enhancing immunity according to claim 1, comprising the following steps:
A. pretreatment: weighing the raw materials of rhizoma polygonati, medlar, morinda officinalis, american ginseng, schisandra chinensis and agilawood respectively according to a formula, drying, crushing and sieving the rhizoma polygonati, the medlar and the morinda officinalis to obtain a material a for standby; drying, crushing and sieving American ginseng and schisandra chinensis to obtain a material b for standby; drying, crushing and sieving agilawood to obtain agilawood powder for later use;
B. extracting:
(1) Extracting the material a by water to obtain an extracting solution, concentrating and drying to obtain a dry paste a;
(2) Adding the material b into ethanol solution with the volume percentage concentration of 30% -50%, carrying out reflux extraction to obtain an extracting solution, concentrating and drying to obtain dry paste b;
(3) Adding the agilawood powder into an ethanol solution with the volume percentage concentration of 80% -100%, soaking, extracting under reflux to obtain an extracting solution, concentrating, and drying to obtain an agilawood ethanol extract;
C. post-treatment: mixing, pulverizing and mixing the dry extract a, the dry extract b and the ethanol extract of lignum Aquilariae Resinatum to obtain a material c, and making into the final product.
6. The method for preparing the traditional Chinese medicine composition according to claim 5, comprising the following steps:
A. pretreatment: weighing the raw materials of rhizoma polygonati, medlar, morinda officinalis, american ginseng, shizandra berry and agilawood according to a formula, drying, crushing the rhizoma polygonati, the medlar and the morinda officinalis, and sieving the materials with a 40-60-mesh sieve to obtain a material a for standby; drying and crushing American ginseng and schisandra chinensis, and sieving with a 40-60 mesh sieve to obtain a material b for standby; drying and crushing agilawood with ethanol extract content of 10% -20%, and sieving with a 8-12 mesh sieve to obtain agilawood powder for later use;
B. extracting:
(1) Adding drinking water with the volume 6-8 times of the weight of the material a into the material a, reflux-extracting for 1-3 times at 95-100 ℃ for 30-90min each time, mixing the extracting solutions, concentrating, and drying to obtain dry paste a;
(2) Adding ethanol solution with volume percentage concentration of 30% -50% and weight of 6-8 times of the material b into the material b, reflux-extracting for 1-3 times at 60-80 ℃ for 60-120min each time, mixing the extracting solutions, concentrating, and drying to obtain dry paste b;
(3) Adding lignum Aquilariae Resinatum powder into 80-100% ethanol solution with volume percentage concentration of 15-25 times, soaking for 40-80min, reflux extracting at 60-80deg.C for 2-3 times, each time for 60-80min, mixing extractive solutions, concentrating, and drying to obtain lignum Aquilariae Resinatum ethanol extract;
C. post-treatment: mixing and pulverizing the dry extract a, the dry extract b and the ethanol extract of eaglewood to obtain a material c, and preparing the target traditional Chinese medicine composition.
7. The method for preparing a Chinese medicinal composition according to claim 6, wherein,
in the step B, the drying is low-temperature vacuum drying, and the drying temperature is 60-80 ℃;
in the step C, the crushing is that the powder is crushed and sieved by a 70-90-mesh sieve.
8. A pharmaceutical preparation for enhancing immunity, which is characterized in that the traditional Chinese medicine composition prepared by the preparation method of any one of claims 5-7 or the traditional Chinese medicine composition of any one of claims 1-4 is added with auxiliary materials acceptable in the processing of medicines or health foods to prepare granules, powder, tablets, capsules or pills.
9. The use of a Chinese medicinal composition prepared by the preparation method of any one of claims 5 to 7 or the Chinese medicinal composition of any one of claims 1 to 4 in the preparation of a medicament or health food for improving human immunity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210723558.7A CN114949114B (en) | 2022-06-24 | 2022-06-24 | Agilawood-containing traditional Chinese medicine composition for enhancing immunity as well as preparation method, preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210723558.7A CN114949114B (en) | 2022-06-24 | 2022-06-24 | Agilawood-containing traditional Chinese medicine composition for enhancing immunity as well as preparation method, preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114949114A CN114949114A (en) | 2022-08-30 |
| CN114949114B true CN114949114B (en) | 2023-09-15 |
Family
ID=82966288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210723558.7A Active CN114949114B (en) | 2022-06-24 | 2022-06-24 | Agilawood-containing traditional Chinese medicine composition for enhancing immunity as well as preparation method, preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114949114B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101773606A (en) * | 2010-03-15 | 2010-07-14 | 武汉代代木生物科技有限公司 | Preparation capable of nursing essence, replenishing qi, refreshing spirit and balancing yin and yang and preparation method thereof |
| CN102626169A (en) * | 2012-04-24 | 2012-08-08 | 哈尔滨工业大学 | Five-taste health-strengthening tea |
| CN103417837A (en) * | 2013-08-26 | 2013-12-04 | 蒋正国 | Medical and edible Chinese wolfberry health maintenance cream and preparing method thereof |
-
2022
- 2022-06-24 CN CN202210723558.7A patent/CN114949114B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101773606A (en) * | 2010-03-15 | 2010-07-14 | 武汉代代木生物科技有限公司 | Preparation capable of nursing essence, replenishing qi, refreshing spirit and balancing yin and yang and preparation method thereof |
| CN102626169A (en) * | 2012-04-24 | 2012-08-08 | 哈尔滨工业大学 | Five-taste health-strengthening tea |
| CN103417837A (en) * | 2013-08-26 | 2013-12-04 | 蒋正国 | Medical and edible Chinese wolfberry health maintenance cream and preparing method thereof |
Non-Patent Citations (1)
| Title |
|---|
| Zhixiang Zhu 等.HHX-5, a derivative of sesquiterpene from Chinese agarwood, suppresses innate and adaptive immunity via inhibiting STAT signaling pathways.European Journal of Pharmacology.2016,412-423. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114949114A (en) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103719498B (en) | A kind of Siberian solomonseal rhizome health-care tea improving immunity and preparation method thereof | |
| CN103689563A (en) | Health-preserving health food formula beneficial for improving sleep and preparation method thereof | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN115350242B (en) | Glycolipid metabolism regulator and preparation method and application thereof | |
| CN106924374B (en) | Composition, preparation method thereof and application of composition in preparation of products for reducing blood sugar and/or blood fat | |
| CN105708970B (en) | A kind of health food with function of blood sugar reduction | |
| CN107412665B (en) | It is a kind of that there is Chinese medicine composition for relieving the effect of alcohol, preventing alcoholic liver injury and its preparation method and application | |
| CN105902827A (en) | Traditional Chinese medicine composition for improving immunity of human body and preparation method thereof | |
| CN114949114B (en) | Agilawood-containing traditional Chinese medicine composition for enhancing immunity as well as preparation method, preparation and application thereof | |
| CN105434777A (en) | Preparation method of traditional Chinese medicine vinum | |
| CN106620475B (en) | Traditional Chinese medicine composition for preventing and treating diabetes cognitive impairment and preparation method thereof | |
| CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN104800771A (en) | Traditional Chinese medicine preparation for treating children sleep terror disorder and preparation method thereof | |
| CN104825817B (en) | A kind of Chinese medicine preparation with antitumor action | |
| CN107823293A (en) | Treat Yao nationality medicine external pulvis of canker sore and preparation method thereof | |
| CN108210651B (en) | A natural medicinal composition for treating diabetic nephropathy, and its preparation method | |
| CN113750200A (en) | Anti-fatigue instant food ginseng and rhizoma polygonati solid particles | |
| CN112402569A (en) | Anti-fatigue health product and preparation method thereof | |
| CN112293630A (en) | Plant beverage for promoting lactation and preparation method thereof | |
| CN112915175A (en) | Anti-fatigue traditional Chinese medicine composition tablet and preparation method thereof | |
| CN108853340A (en) | A kind of Chinese medicine of nourishing the liver and kidney and preparation method thereof | |
| CN116920039B (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN108478701A (en) | A kind of lozenge of strengthen immunity | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN105561101A (en) | Traditional Chinese medicine preparation for treating phthisis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |